



**NM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT
THIRD QUARTER OF 2019 (2019Q3)**

**Substance Abuse Epidemiology Section
Prescription Drug Overdose Prevention Program
Injury and Behavioral Epidemiology Bureau
Epidemiology and Response Division**



This report is produced quarterly to track indicators related to drug overdose prevention. The indicators reported here allow for the tracking of three key interventions for prescription drug overdose: improving prescribing of controlled substances, increasing the availability of treatment for opioid dependence, and the increasing availability of naloxone in the community.

This report is based on calendar quarters: Q1 is January-March of the calendar year.




Data for this report were drawn from several sources:

1. The Prescription Monitoring Program (PMP) operated by the NM Board of Pharmacy, which collects data on every controlled substance prescription filled in New Mexico.
2. New Mexico Medicaid in the Human Services Department, for data on methadone treatment paid by Medicaid, and for data on claims paid for naloxone prescriptions at pharmacies.
3. The State Opioid Treatment Authority in the Human Services Department for data on methadone treatment programs operating in New Mexico.
4. The NM Department of Health Syringe Services Program for data on naloxone distributed via syringe exchange sites
5. The Behavioral Health Services Division in the Human Services Department for data on naloxone distributed through Office of Substance Abuse Prevention programs.

I. New Mexico Prescription Monitoring Program (PMP) Measures



I. New Mexico Prescription Monitoring Program (PMP) Measures



I. New Mexico Prescription Monitoring Program (PMP) Measures

Totals

Year and Quarter	2018Q3	2019Q2	2019Q3	Quarterly % Change 2019Q2 vs 2019Q3	Quarterly % Change 2018Q3 vs 2019Q3
Total number of controlled substance patients	229,964	225,162	216,758	-3.7%	-5.7%
Number of patients receiving opioids	148,364	143,902	134,851	-6.3%	-9.1%
Number of opioid prescriptions filled (excluding buprenorphine/naloxone)	319,458	306,808	292,531	-4.7%	-8.4%
Number of buprenorphine/naloxone prescriptions filled	23,742	24,504	24,675	0.7%	3.9%
Number of high dose (>=90 MME/day) opioid prescriptions excluding buprenorphine/naloxone	37,558	33,553	32,416	-3.4%	-13.7%
Total MME of opioids filled - excluding buprenorphine/naloxone	288,065,589	266,371,805	259,268,334	-2.7%	-10.0%
Total MME/prescription-day	56	55	56	1.4%	-0.1%
Number of patients receiving benzodiazepines	85,073	80,916	79,727	-1.5%	-6.3%
Number of benzodiazepine prescriptions filled	187,229	177,703	174,717	-1.7%	-6.7%
Number of high-dose(>=40 DME/day) benzodiazepine prescriptions filled	32,738	30,241	29,663	-1.9%	-9.4%
Total DME of benzodiazepines filled	99,752,073	91,292,304	88,807,266	-2.7%	-11.0%
Total DME/patient	1,173	1,128	1,114	-1.3%	-5.0%

SOURCE OF DATA: NM Prescription Monitoring Program (PMP), NM Prescribers with at least 20 controlled substance patients

MME = Morphine Milligram Equivalent; reference at http://www.cdc.gov/drugoverdose/pdf/calculating_total_daily_dose-a.pdf

DME = Diazepam Milligram Equivalent; reference at <http://archinte.jamanetwork.com/article.aspx?articleid=217249>, 2004

I. New Mexico Prescription Monitoring Program (PMP) Measures

Number of Patients with:

Year and Quarter	2018Q3	2019Q2	2019Q3	Quarterly % Change 2019Q2 vs 2019Q3	Quarterly % Change 2018Q3 vs 2019Q3
High dose opioids (>=90 MME/day)	13,186	11,762	11,298	-3.9%	-14.3%
High dose benzodiazepines (>=40 DME/day)	14,324	13,332	13,089	-1.8%	-8.6%
Opioids >=90 days and <90% of days in past 6 months	19,672	17,699	17,287	-2.3%	-12.1%
Opioids >=90% of days in past 6 months	30,730	29,519	29,001	-1.8%	-5.6%
Benzodiazepines >=90 days and <90% of days in past 6 months	22,290	20,563	19,919	-3.1%	-10.6%
Benzodiazepines >=90% of days in past 6 months	24,473	23,142	22,644	-2.2%	-7.5%
Overlapping prescriptions of opioids from different prescribers (>=10 days total overlap)	3,681	3,059	2,751	-10.1%	-25.3%
Overlapping prescriptions of benzodiazepines from different prescribers (>=10 days total overlap)	2,310	1,842	1,755	-4.7%	-24.0%
Concurrent opioid and benzodiazepines (>=10 days overlap)	18,655	15,840	14,822	-6.4%	-20.5%
High dose opioids (>=90 MME/day) plus benzodiazepines	3,418	2,873	2,657	-7.5%	-22.3%
Multiple prescribers and pharmacies: 4 or more prescribers or 4 or more pharmacies in 3 months	2,713	2,137	2,126	-0.5%	-21.6%
New Opioid Patients with at least 30 days of coverage in the past 3 months	3,120	2,563	2,353	-8.2%	-24.6%
New Benzodiazepine Patients with at least 30 days of coverage in the past 3 months	4,307	3,874	3,825	-1.3%	-11.2%

SOURCE OF DATA: NM Prescription Monitoring Program (PMP), NM Prescribers with at least 20 controlled substance patients

I. New Mexico Prescription Monitoring Program (PMP) Measures


New Mexico Prescribers with at least 20 controlled substance patients:

Year and Quarter	2018Q3	2019Q2	2019Q3	Quarterly % Change 2019Q2 vs 2019Q3	Quarterly % Change 2018Q3 vs 2019Q3
Total active controlled substance prescribers	3,159	3,156	3,059	-3.1%	-3.2%
Prescribers with at least 50% high dose of opioid prescriptions, excluding treatment prescribers	61	57	58	1.8%	-4.9%
Prescribers with at least 50% high dose of benzodiazepine prescriptions	143	134	133	-0.7%	-7.0%
Prescribers with at least 25% of patients having concurrent opioids and benzodiazepines	18	7	7	0.0%	-61.1%
Some PMP Use: Requested reports on at least 25% of patients estimated to require them	1,186	1,628	1,602	-1.6%	35.1%
Zero PMP Use: Requested no PMP reports on patients filling Controlled Substances	600	344	277	-19.5%	-53.8%
Number of Patients with PMP reports requested by practitioners	128,067	227,340	242,589	6.7%	89.4%
% of Chronic opioid users with a PMP request in the past 3 months*	66.1%	79.1%	79.4%	0.3%	20.0%
% of Chronic benzodiazepine users with a PMP request in the past 3 months*	42.2%	55.9%	57.0%	1.9%	35.0%
% of New Opioid Patients with a PMP request in the past 3 months**	20.7%	32.5%	34.7%	6.8%	67.2%
% of New Benzodiazepine Patients with a PMP request in the past 3 months**	23.1%	35.6%	37.6%	5.8%	63.1%

*Chronic users are those with at least 90 days of coverage in six months.

**New patients are those with more than 4 days of coverage in the quarter and none in the prior quarter.

SOURCE OF DATA: NM Prescription Monitoring Program (PMP), NM Prescribers with at least 20 controlled substance patients



II. Medication Assisted Treatment (Buprenorphine/naloxone and methadone) Measures

Year and Quarter	2018Q3	2019Q2	2019Q3	Quarterly % Change 2019Q2 vs 2019Q3	Quarterly % Change 2018Q3 vs 2019Q3
Treatment (buprenorphine/naloxone) prescribers with at least 10 treatment patients	179	196	204	4.1%	14.0%
Buprenorphine/naloxone patients (>=10 days)	6,083	6,480	6,655	2.7%	9.4%
Buprenorphine/naloxone prescriptions filled	23,742	24,504	24,675	0.7%	3.9%
Total Practitioners with DATA Waiver	614	726	785	8.1%	27.9%
Nurse Practitioners and PA's with DATA Waiver	127	191	224	17.3%	76.4%

Medicaid Methadone Treatment

Number of distinct individuals with methadone claims paid by NM Medicaid	5,338	5,183	5,815	12.2%	8.9%
Number of distinct NM Medicaid providers of methadone	11	11	11	0.0%	0.0%

Methadone Treatment Programs by Survey Date	Aug 2018	Jul 2019	Nov 2019		
Number of Methadone Treatment Programs	16	17	17	0.0%	6.3%
Number of Methadone Treatment Patients in those Programs	6,259	6,920	6,964	0.6%	11.3%


DATA Waivered provider data are as of the last month of the quarter

Sources:

Buprenorphine/naloxone data: NM Prescription Monitoring Program

Methadone data: NM Human Services Department, State Opioid Treatment Authority; NM Medicaid

DATA Waivered providers: US DEA Diversion Control Division



III. Naloxone Distribution and Usage Measures

Year and Quarter	2018Q3	2019Q2	2019Q3	Quarterly % Change 2019Q2 vs 2019Q3	Quarterly % Change 2018Q3 vs 2019Q3
New Enrollments in NM State Government Naloxone Programs	2,502	2,367	3,312	39.9%	32.4%
Total Number of NM Naloxone Doses distributed	8,574	15,608	14,072	-9.8%	64.1%
Total Number of NM Reported Reversals	647	1,170	926	-20.9%	43.1%

Year and Quarter	2018Q3	2019Q2	2019Q3	Quarterly % Change 2019Q2 vs 2019Q3	Quarterly % Change 2018Q3 vs 2019Q3
Pharmacies Presenting Medicaid Naloxone Claims	224	290	264	-9.0%	17.9%
Number of Medicaid Naloxone Claims Processed	1,854	3,737	7,639	104.4%	312.0%

Some naloxone doses were given to organizations and may not have been distributed in that quarter.

Reported Reversals are not necessarily individual level data, as one person could have overdosed and been reversed more than once. Data on reversals are combined across several agencies and programs, and the definition of a reversal may vary.

An outpatient pharmacy could present claims in more than one quarter. The total number was obtained by counting each pharmacy once. There were 369 outpatient Pharmacies with a NM address in 2017 according to the Board of Pharmacy.

All law enforcement agencies have been contacted about naloxone training and use. The data reported reflect the number of agencies where at least some officers are carrying naloxone.

Sources: NM DOH Programs; NM HSD/BHSD Programs; NM Medicaid

